# Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer

> **NCT03647514** · NA · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Abraxane
- **DRUG:** Xeloda

## Key facts

- **NCT ID:** NCT03647514
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647514, "Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03647514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*